This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AbbVie-Allergan review's removal from fast track in Brazil shouldn't raise red flag

By Ana Paula Candil ( November 12, 2019, 22:47 GMT | Insight) -- A decision turning the expedited probe of AbbVie’s proposed merger with Allergan into a full-form review by the Brazilian competition authority is merely procedural and doesn’t necessarily mean the agency has concerns about market concentration resulting from the deal, MLex has learned. Because the companies’ combined market shares are greater than 20 percent in certain scenarios, their transaction doesn’t fit the agency's threshold for fast-track deals.A decision turning the expedited probe of AbbVie’s proposed merger with Allergan into a full-form review by the Brazilian competition authority is merely procedural and doesn’t necessarily mean the agency has concerns about market concentration resulting from the deal, MLex has learned. Because the companies’ combined market shares are greater than 20 percent in certain scenarios, their transaction doesn’t fit the agency's threshold for fast-track deals....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login